- Details
- Zach Klaassen speaks with Brent Rose about advances in bladder-sparing therapies for localized bladder cancer. Dr. Rose highlights the surprising underutilization of chemo-radiation in bladder cancer treatment, despite its established role in other cancers and the significant risks and quality of life issues associated with cystectomy. He underscores the efficacy of chemo-radiation, drawing on dat...
|
- Details
- Sima Porten provides an overview of the SunRISe-5 trial, a Phase III study evaluating TAR-200, a novel drug delivery system for patients with recurrent high-risk non-muscle invasive bladder cancer (NMIBC) who have not responded to BCG treatment. Speaking with Dr. Sam Chang of Vanderbilt, Dr. Porten explains that TAR-200 releases gemcitabine directly into the bladder over a sustained period, offeri...
|
- Details
- José Daniel Subiela Henriquez presented findings from his multicenter study on BCG therapy for very high-risk non-muscle-invasive bladder cancer (NMIBC). Dr. Subiela's research evaluates the effectiveness of BCG in a group where the European Association of Urology (EAU) had recommended radical cystectomy due to high progression risks. His study, involving 640 patients over 13 years, suggests that...
|
- Details
- Yair Lotan discusses the STRATA trial, a multicenter study comparing the Cxbladder Triage test to traditional cystoscopy in patients with microhematuria. This trial explores whether a high negative predictive value biomarker test can safely reduce the number of unnecessary cystoscopies in low-risk patients. Microhematuria, a common condition affecting millions annually in the U.S., is frequently o...
|
- Details
- Ashish Kamat hosts a discussion with Roger Li and Trinity Bivalacqua on the CORE-001 study evaluating cretostimogene grenadenorepvec and pembrolizumab for BCG-unresponsive CIS. Dr. Li highlights the 83% complete response rate at any time, 57.1% at 12 months, and 54.3% at 24 months, noting the therapy's durability and lack of progression to muscle-invasive or metastatic disease. The combination the...
|
- Details
- Sam Chang interviews Edward Messing about his research on using apalutamide for non-muscle invasive bladder cancer. Dr. Messing discusses a trial aiming to explore whether antiandrogens like apalutamide can prevent bladder cancer recurrence, given its higher prevalence in men. This molecular proof-of-principle study, sponsored by the National Cancer Institute, focuses on the role of androgen recep...
|
- Details
- Sam Chang interviews Karim Chamie about pivotal clinical trials in urothelial carcinoma presented at AUA 2024. Dr. Chamie discusses the MoonRISe-1 trial, a Phase III study on TAR-210 (an erdafitinib intravesical delivery system) for intermediate-risk non-muscle-invasive bladder cancer, highlighting its innovative approach and potential to change the treatment landscape. He also reviews the SunRISe...
|
- Details
- Sam Chang interviews Neal Shore about the KEYNOTE-676 trial. This global study evaluates the efficacy of combining Pembrolizumab with BCG induction and maintenance in patients who had previously received an induction course of BCG without maintenance. Dr. Shore discusses the study’s aim to enhance the effectiveness of BCG therapy in non-muscle invasive bladder cancer (NMIBC) by adding a checkpoint...
|
- Details
- Sam Chang interviews Woodson Smelser to discuss takeaways from the AUA Annual Meeting in urothelial carcinoma, highlighting the rapid advancements in non-muscle invasive bladder cancer therapies. He emphasizes the importance of new FDA-approved agents like Pembrolizumab, Nadofaragene, and Nogapendekin. Dr. Smelser also reviews clinical trials, such as the TAR-200 device and the CG0070 adenovirus....
|
- Details
- Ashish Kamat hosts a discussion with Matt Galsky and Neal Shore on the latest advancements in bladder cancer treatment, focusing on immunotherapy for advanced bladder cancer and the associated survival benefits. He emphasizes the importance of recognizing and managing immune-related toxicities. Dr. Shore discusses the application of immunotherapy in earlier stages of disease, mentioning pembrolizu...
|
